Prognostic significance of lymphocyte patterns in multiple myeloma patients after autologous transplant

被引:4
作者
Stork, Martin [1 ]
Bezdekova, Renata [2 ]
Kralova, Romana [2 ]
Sandecka, Viera [1 ]
Adam, Zdenek [1 ]
Krejci, Marta [1 ]
Boichuk, Ivanna [1 ]
Knechtova, Zdenka [1 ]
Brozova, Lucie [3 ]
Sevcikova, Sabina [4 ]
Rihova, Lucie [2 ]
Pour, Ludek [1 ]
机构
[1] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
[2] Univ Hosp Brno, Dept Clin Hematol, Brno, Czech Republic
[3] Inst Biostat & Anal Ltd, Brno, Czech Republic
[4] Masaryk Univ, Fac Med, Dept Pathophysiol, Babak Myeloma Grp, Brno, Czech Republic
关键词
multiple myeloma; minimal residual disease; lymphocyte; flow cytometry; MINIMAL RESIDUAL DISEASE; PERIPHERAL-BLOOD; BONE-MARROW; CELLS; SURVIVAL; PROGRESSION; SUBSETS; THERAPY; IMPACT; NKT;
D O I
10.4149/neo_2021_200814N861
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Despite the high efficacy of current induction regimens, most multiple myeloma (MM) patients relapse over time. The link between changes in the immune system and the prognosis of the disease is still not entirely clear. Therefore, we analyzed whether the pattern of bone marrow (BM) lymphocytes during routine BM examination after autologous stem cell transplant (ASCT) is related to disease prognosis or MRD negative complete remission. From 2009 to 2018, 98 MM patients underwent routine BM testing after the first ASCT. Using multi-parametric flow cytometry, twelve BM lymphocyte subtypes were analyzed. In 60% of patients who achieved a complete response (CR), MRD by flow cytometric analysis (sensitivity threshold 10-6) was evaluated. We found an association of relative proportion of BM lymphocyte subtypes with treatment response, progression-free survival (PFS), overall survival (OS), and minimal residual disease (MRD) negativity. Higher relative proportion of memory B cells was associated with inferior median PFS [HR 1.089 (95% CI: 1.023-1.160), p=0.0081 and median OS [HR 1.170 (95% CI: 1.074-1.274), p<0.001]. In non-responding patients (minimal response and worse), higher proportion of memory B cells was found when compared to patients achieving CR [3.8% (range 0.5-35.0) vs. 1.0% (range 0.1-12.5); p=0.0011. No significant association of BM lymphocyte subtypes proportion with MRD negative CR was found. Our results show that changes in BM lymphocyte subsets including memory B cells may have prognostic value in MM patients after ASCT.
引用
收藏
页码:519 / 527
页数:9
相关论文
共 50 条
  • [31] Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation
    Pasvolsky, Oren
    Wang, Zhongya
    Milton, Denai R.
    Tanner, Mark R.
    Bashir, Qaiser
    Srour, Samer
    Saini, Neeraj
    Lin, Paul
    Ramdial, Jeremy
    Nieto, Yago
    Tang, Guilin
    Kebriaei, Partow
    Aljawai, Yosra
    Khan, Hina N.
    Lee, Hans C.
    Ye, Christine
    Patel, Krina K.
    Thomas, Sheeba K.
    Orlowski, Robert Z.
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [32] Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma
    Fernandez de Larrea, C.
    Jimenez, R.
    Rosinol, L.
    Gine, E.
    Tovar, N.
    Cibeira, M. T.
    Fernandez-Aviles, F.
    Martinez, C.
    Rovira, M.
    Blade, J.
    BONE MARROW TRANSPLANTATION, 2014, 49 (02) : 223 - 227
  • [33] Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades
    Pasvolsky, Oren
    Marcoux, Curtis
    Dai, Jianliang
    Tanner, Mark R.
    Syed, Naureen
    Bashir, Qaiser
    Milton, Denai R.
    Srour, Samer
    Saini, Neeraj
    Lin, Paul
    Ramdial, Jeremy
    Nieto, Yago
    Tang, Guilin
    Aljawai, Yosra
    Lee, Hans C.
    Gaballa, Mahmoud R.
    Patel, Krina K.
    Kebriaei, Partow
    Thomas, Sheeba K.
    Orlowski, Robert Z.
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (08): : 772e1 - 772e11
  • [34] Longitudinal Flow Cytometry Identified "Minimal Residual Disease" (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma
    Gu, Jingli
    Liu, Junru
    Chen, Meilan
    Huang, Beihui
    Li, Juan
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (12) : 2568 - 2574
  • [35] Absolute lymphocyte count as a prognostic marker in newly diagnosed multiple myeloma patients
    Suriu, C.
    Akria, L.
    Azoulay, D.
    Shaoul, E.
    Barhoum, M.
    Braester, A.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 (03) : e56 - e59
  • [36] Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
    Ozkurt, Zuebeyde Nur
    Sucak, Gulsan Tuerkoez
    Aki, Sahika Zeynep
    Yagci, Munci
    Haznedar, Rauf
    CANCER INVESTIGATION, 2017, 35 (03) : 195 - 201
  • [37] Evaluation of the Prognostic Value of the Mayo Additive Staging System and Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients
    Song, Yichuan
    Zhao, Rui
    Fu, Wenxuan
    Zhao, Jing
    Wang, Qingtao
    Zhang, Rui
    CANCER MEDICINE, 2024, 13 (21):
  • [38] Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
    Sun, Qian
    Li, Xiaozhe
    Gu, Jingli
    Huang, Beihui
    Liu, Junru
    Chen, Meilan
    Li, Juan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [39] Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
    de Tute, Ruth M.
    Pawlyn, Charlotte
    Cairns, David A.
    Davies, Faith E.
    Menzies, Tom
    Rawstron, Andy
    Jones, John R.
    Hockaday, Anna
    Henderson, Rowena
    Cook, Gordon
    Drayson, Mark T.
    Jenner, Matthew W.
    Kaiser, Martin F.
    Gregory, Walter M.
    Morgan, Gareth J.
    Jackson, Graham H.
    Owen, Roger G.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2889 - +
  • [40] IMMUNOPHENOTYPE OF BONE MARROW PLASMA CELLS IN PATIENTS WITH MULTIPLE MYELOMA DURING HIGH-DOSE CHEMOTHERAPY AND AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
    Mendeleeva, L. P.
    Akhundova, F. M.
    Naumova, E., V
    Galtseva, I., V
    Pokrovskaya, O. S.
    Soloviev, M., V
    Gribanova, E. O.
    Kuzmina, L. A.
    Parovichnikova, E. N.
    Savchenko, V. G.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2017, 62 (01): : 4 - 8